Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-SELECT Single-Target CAR-NK Cells
- Development stage
- Phase 2
- Lead developer
- Essen Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-SELECT Single-Target CAR-NK Cells is an investigational allogeneic, donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Essen Biotech. This cell-based immunotherapy involves genetically modifying NK cells from healthy donors to express a single CAR construct. The specific target antigen is selected for each patient based on tumor profiling via tissue or liquid biopsy, allowing for a personalized approach to treating various advanced solid tumors. The therapy is currently being evaluated in the Phase 1/2 SELECT-CAR-NK clinical trial for indications including breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer, glioblastoma, melanoma, and liver cancer.
- Other names
- EB-SELECT Single-Target CAR-NK
Beyond the preview
Go deeper on EB-SELECT Single-Target CAR-NK Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-SELECT Single-Target CAR-NK Cells.